WOBURN, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that it plans to participate in the following two dermatology conferences in January:
- 2022 Winter Clinical Dermatology Conference at the Grand Hyatt in Kauai, January 14-19, 2022
- Maui Derm for Dermatologists 2022 at the Grand Wailea, January 24-28, 2022
At each conference, clinical data for Biofrontera’s two FDA-approved products, Ameluz® and Xepi®, will be presented. The presentations will provide an overview of multiple recent studies involving photodynamic therapy (PDT) used in combination with the flagship product Ameluz® (Ameluz-PDT), such as the recently published pharmacokinetic data, and findings from investigator-initiated trials (IIT). The presentations will be complemented by continuing medical education (CME) sessions on actinic keratosis (AK), PDT and the recent FDA-approval of the new PDT-lamp RhodoLED XL.
In addition, the Company will host an expert advisory board meeting (Ad Board) with nine dermatologists at the 2022 Winter Clinical Dermatology Conference. The goal of the Ad Board is to gain insight and guidance from experts on key clinical and scientific messaging that address unmet needs as well as approaches to best communicate clinical data findings, including Biofrontera’s recent regulatory approval of the RhodoLED XL lamp.
Erica Monaco, Chief Executive Officer of Biofrontera Inc., commented, “We are extremely pleased with the growing body of high-quality scientific data for each product in our portfolio. The published clinical data highlight advantages of using Ameluz-PDT in the treatment of AK, a common precursor to non-melanoma skin cancer. The IITs also represent confidence and interest within the dermatology community, strengthening the competitive positioning of Ameluz-PDT.”
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company’s licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit www.biofrontera-us.com.
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to the expected trading commencement and closing dates. We have based these forward-looking statements on our current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, including, but not limited to, the impact of extraordinary external events, such as the current COVID-19 pandemic; any changes in the Company’s relationship with the Licensor; the outcome of the Company’s litigation with DUSA Pharmaceuticals, Inc., including the trial scheduled to begin at the end of November; the Company’s ability to achieve and sustain profitability; whether the current disruptions in the supply chain will impact the Company’s ability to obtain and distribute its licensed products; changes in the practices of healthcare providers, including any changes to the coverage, reimbursement and pricing for procedures using the Company’s licensed products; the uncertainties inherent in the initiation and conduct of clinical trials; availability and timing of data from clinical trials; whether results of early clinical trials or trials in different disease indications will be indicative of the results of ongoing or future trials; whether results of the studies described above will be indicative of results for any future clinical trials and studies of Ameluz® in combination with BF-RhodoLED®; uncertainties associated with regulatory review of clinical trials and applications for marketing approvals; whether the market opportunity for Ameluz® in combination with BF-RhodoLED® is consistent with the Company’s expectations; whether the Company will be able to successfully transition to a public company operating independently of Biofrontera AG; the Company’s ability to retain and hire key personnel; the sufficiency of cash resources and need for additional financing and other factors that may be disclosed in the Company’s filings with the SEC, which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. The company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.
Contacts
Biofrontera Inc.
Pamela Keck
+1 781 486 1539
us-ir@biofrontera.com
LHA Investor Relations
Tirth T. Patel
+1 212 201 6614
tpatel@lhai.com
# # #
